<DOC>
	<DOCNO>NCT00193180</DOCNO>
	<brief_summary>This trial evaluate novel combination docetaxel imatinib first second line therapy advance breast cancer aim achieve high effectiveness potentially reduce side effect .</brief_summary>
	<brief_title>Docetaxel Plus Imatinib Mesylate Metastatic Breast Cancer</brief_title>
	<detailed_description>All patient study receive docetaxel 30 mg/m2 weekly 3 consecutive week 28-day cycle , along continuous imatinib mesylate . Initially , imatinib mesylate give dose 600 mg orally daily , begin concurrently first dose docetaxel ; however , first 15 patient treat become evident imatinib dose tolerable , subsequent patient receive imatinib mesylate 400 mg orally daily</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>To include study , must meet following criterion : Metastatic breast cancer confirm biopsy No one prior chemotherapy regimen metastatic breast cancer Able perform activity daily live minimal assistance Adequate bone marrow , liver kidney function Age 18 year older Give write informed consent You participate study follow apply : Moderate severe peripheral neuropathy Uncontrolled blood pressure uncontrolled heart beat irregularity Diabetes Mellitus fast blood sugar great 200 mg % Significant heart disease within prior 6 month Severe uncontrolled medical disease Active uncontrolled infection Known chronic liver disease Known diagnosis HIV infection Pregnant breast feeding female Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>